Devonian Health Group (GSD) Q3 2025 earnings summary

Executive summary

• Third quarter revenues rose 36% year-over-year, driven by DEXLANSOPRAZOLE sales, which ended in April 2025.

• Net loss for the quarter was $4.8 million, or $0.032 per share, primarily due to a non-cash impairment loss.

• Management highlighted continued progress in Thykamine™ development, supported by Altius revenues.

• Leadership changes included the appointment of Dr. Andre Boulet as CEO and Luc Gregoire as EVP Strategy.

Financial highlights

• Distribution revenue for Q3 was $7.36 million, mainly from DEXLANSOPRAZOLE.

• A non-cash impairment loss of $4.84 million was recorded due to the expiration of the DEXLANSOPRAZOLE agreement.

• DEXLANSOPRAZOLE represented 95% of revenue for the fiscal year to date.

• Net loss of $4.8 million for the quarter, entirely attributable to the impairment loss.

Outlook and guidance

• Liquidity remains sufficient to advance Thykamine™ development despite the end of DEXLANSOPRAZOLE revenues.

• Management continues to focus on expanding Thykamine™ applications in inflammatory diseases.